A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation
A phase 2 trial of Fulzerasib and Ivonescimab in KRAS G12C-mutant non-small-cell lung cancer, run by Shanghai Chest Hospital, not yet recruiting.
Overview
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation is a phase 2 interventional study registered as NCT06936644 by Shanghai Chest Hospital, with 39 participants planned, started 2025-04-30 and due to reach its primary completion in 2027-04-30. Interventions recorded: IBI351+AK112. Conditions recorded: KRAS G12C Lung Cancer.
Linked to the drug Fulzerasib because the registry names it among its interventions and KRAS G12C-mutant non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialNeoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases
Shares Fulzerasib and the tag pipeline.
- TrialA Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
Shares Fulzerasib and the tag pipeline.
- TrialFirst-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
Shares Ivonescimab and the tag pipeline.
- TrialA Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Shares Ivonescimab and the tag pipeline.
- TrialStudy of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
Shares KRAS G12C-mutant non-small-cell lung cancer and the tag pipeline.
- TrialA Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Shares KRAS G12C-mutant non-small-cell lung cancer and the tag pipeline.
- TrialStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Shares KRAS G12C-mutant non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Shares Ivonescimab and the tag pipeline.